AnaptysBio Announces Presentation at the J.P. Morgan 36th Annual Healthcare Conference
January 02 2018 - 6:30AM
AnaptysBio, Inc. (Nasdaq:ANAB), a clinical-stage biotechnology
company developing first-in-class antibody product candidates
focused on unmet medical needs in inflammation, today announced
that Hamza Suria, chief executive officer of AnaptysBio, will
present at the J.P. Morgan 36th Annual Healthcare Conference on
Tuesday, Jan. 9, 2018 at 12:00 p.m. PT at the Westin St. Francis in
San Francisco.
A webcast of the presentation will be available through the
investor section of the AnaptysBio website. Replays of the webcast
will be available for 90 days following the events.
About AnaptysBioAnaptysBio is a clinical-stage
biotechnology company developing first-in-class antibody product
candidates focused on unmet medical needs in inflammation. The
company’s proprietary anti-inflammatory pipeline includes its
anti-IL-33 antibody (ANB020) for the treatment of
moderate-to-severe adult atopic dermatitis, severe adult peanut
allergy and severe adult eosinophilic asthma; its anti-IL-36R
antibody (ANB019) for the treatment of rare inflammatory diseases,
including generalized pustular psoriasis and palmo-plantar pustular
psoriasis; and a portfolio of checkpoint receptor agonist
antibodies for the treatment of certain autoimmune diseases where
immune checkpoint receptors are insufficiently activated, which
have demonstrated efficacy in an animal model of graft-versus-host
disease. AnaptysBio’s antibody pipeline has been developed using
its proprietary somatic hypermutation (SHM) platform, which uses in
vitro SHM for antibody discovery and is designed to replicate key
features of the human immune system to overcome the limitations of
competing antibody discovery technologies. AnaptysBio has also
developed multiple therapeutic antibodies in an immuno-oncology
partnership with TESARO and an inflammation partnership with
Celgene, including an anti-PD-1 antagonist antibody (TSR-042), an
anti-TIM-3 antagonist antibody (TSR-022) and an anti-LAG-3
antagonist antibody (TSR-033), which are currently under clinical
development with TESARO, and an anti-PD-1 checkpoint agonist
antibody (CC-90006) currently in the clinic with Celgene.
Contact:Monique AllaireTHRUST Investor
Relations617.895.9511monique@thrustir.com
Chelcie ListerTHRUST Investor
Relations910.777.3049Chelcie@thrustir.com
AnaptysBio (NASDAQ:ANAB)
Historical Stock Chart
From Mar 2024 to Apr 2024
AnaptysBio (NASDAQ:ANAB)
Historical Stock Chart
From Apr 2023 to Apr 2024